Nuheara Limited Overview
| Field | Former listed entity | Current operating business |
|---|---|---|
| Legal name | Nuheara Limited (In Liquidation) | Orecchio Pty Ltd, trading as Nuheara |
| Company number | ACN 125 167 133 | ACN 684 518 723 |
| Status (Oct 2026) | In liquidation since 19 June 2025. KPMG liquidators targeted finalisation on or before 30 September 2026; no public confirmation of finalisation was located | Private company operating the Nuheara brand, website and product range |
| Website | http://www.nuheara.com (now operated by Orecchio) | www.nuheara.com (footer reads "©2025 Orecchio Pty Ltd T/A Nuheara") |
| Country | Australia | Australia |
| Exchange / ticker | ASX: NUH (suspended 1 March 2024; CHESS approval suspended 7 August 2024; subsequently removed from the official list); US OTC: NUHRF | Not listed |
Core identifiers (former listed entity)
| Field | Detail | Source |
|---|---|---|
| Former names | Wild Acre Metals Limited (the ASX shell Nuheara reverse-took-over in 2016) | ChannelNews, Aug 2024 |
| Founding year (operating business) | 2015 (Nuheara founded by Justin Miller and David Cannington) | Craft.co profile; NewsWire, Aug 2024 |
| Incorporation (listed shell) | 2007 (ACN 125 167 133 era registration); Western Australia governing law used in DOCA | ROIC.ai profile; VA Supp. Report |
| Incorporation jurisdiction | Australia (Corporations Act 2001) | KPMG reports |
| Headquarters (historical) | 190 Aberdeen Street, Northbridge, WA 6003. Vacated during administration to cut overheads | Nuheara ASX releases 2023; VA Supp. Report |
| ASX listing | 2016, via reverse takeover of Wild Acre Metals | ChannelNews, Aug 2024 |
| ISIN / CUSIP | — | — |
| Fiscal year end | 30 June | 4E filings FY2018–FY2023 |
| Employees | 22 at administration (Aug 2024), including a US sales representative; 14 at completion of the sale to Orecchio (Mar 2025), all of whom accepted employment with Orecchio. A 3-year trend was not publicly disclosed | Audiology Worldnews, Aug 2024; Liquidator's Report |
| Auditor | Walker Wayland (independent reviewer of the H1 FY2021 half-year report). | H1 FY2021 report |
| Market capitalisation (current) | Nil equity value. Shareholders received a liquidator's declaration on 24 June 2025 under s104-145 of the Income Tax Assessment Act 1997, which allows a capital loss to be claimed on shares. Last reported market capitalisation was about A$21m around the August 2024 administration | KPMG creditor portal; NewsWire, Aug 2024 |
| Administrators / liquidators | Martin Jones, Matthew Woods (and Clint Joseph as administrator) of KPMG Perth | KPMG creditor portal |
Nuheara was a Perth-based hearing-technology company that tried to merge two categories: consumer true-wireless earbuds and medical-grade hearing assistance. Its proprietary Ear ID personalisation, its hybrid active noise cancellation and its "World Blend" / speech-in-noise controls powered the IQbuds family. They also powered the HP Hearing PRO, which in 2022 became the first product cleared through the FDA 510(k) pathway under the new self-fitting OTC hearing aid product code (QUH).
Nuheara's opportunity was the 2022 US OTC hearing-aid rule. Its weakness was chronic under-scale. Revenue peaked at A$12.6m in FY2021 on a one-off HP OEM order, then fell to A$1.9m by FY2023, while annual losses of A$7–14m were funded by repeated equity raises. Its decision to depend on Realtek for a next-generation single-chip design made its largest shareholder also its sole secured creditor and critical supplier. That concentration proved fatal. The brand and IP now survive inside a privately funded shareholder vehicle, Orecchio Pty Ltd.
What the company did
Nuheara designed, developed and commercialised multi-functional "hearables": wireless earbuds that combine audio streaming and calls with hearing enhancement, noise control and personalised sound. Over time the products were regulated as medical devices in key markets. The administrators described the group as specialising in innovative over-the-counter earbuds offering enhanced hearing and noise reduction, selling mainly in Australia, the United States and Canada (VA Supp. Report, Feb 2025).
Company self-description (paraphrased from Nuheara's boilerplate in FY2023 releases): Nuheara described itself as a global pioneer in hearable products with proprietary personalised hearing technology. It noted that its third-generation IQbuds² MAX (2020) was recognised by TIME as a Best Invention. It said its products were sold direct-to-consumer and through retail, addressing demand from people with mild to moderate hearing loss.
Independent characterisation: Nuheara was a sub-scale, fabless device designer with outsourced manufacturing. It sat between consumer electronics (crowded and low-margin) and hearing healthcare (regulated, dominated by five incumbents). Its intellectual property was mainly software and signal-processing know-how: Ear ID self-fitting, noise control and fitting algorithms. Its hardware relied on third-party chipsets, with Realtek as the strategic chipset partner from May 2022.
Business and revenue model
| Revenue stream | Description | Evidence |
|---|---|---|
| Branded product sales (DTC) | IQbuds² MAX, IQstream TV, Bluetooth Transmitter and accessories sold via nuheara.com | Company website; FY2021 annual report commentary on record DTC sales |
| Retail / channel sales | US retailers including Best Buy, Crutchfield, Amazon and Target.com (from Feb 2023); Australian channels including NDIS-funded purchases | ASX release 28 Feb 2023; NDIS registration coverage |
| OEM / co-brand manufacture | HP-branded products made by Nuheara under a three-year manufacturing and supply agreement with HP Inc. (announced in the Dec 2020 quarter). This included the HP Hearing PRO OTC hearing aid | Quarterly report Q2 FY2021; H1 FY2022 report (OEM income of A$3.77m in H1 FY2021) |
| Licensing / royalty | Contemplated under the Realtek Commercial and Royalty Agreement (an MOU dated 17 May 2022). The agreement was never executed | VA Supp. Report; NewsWire Aug 2024 |
| Subscription / services | None disclosed | — |
The product/service/subscription/licensing mix by percentage was not publicly disclosed for any year. The only quantified split is H1 FY2021: OEM income of A$3,772,274 within A$6,909,566 of half-year revenue, about 55% (H1 FY2022 report comparative).
Value-chain position
Nuheara sat at the design, software and brand layer. It specified hardware, developed firmware and apps (Ear ID, IQbuds app, HP Hearing app), managed regulatory clearances (FDA 510(k) K221064) and ran brand and channel management. Manufacturing was outsourced. The administrators' reports name Salutica Allied Solutions Sdn Bhd (Malaysia) as a counterparty with debtor and prepayment balances and a counter-claim, which is consistent with a contract-manufacturing relationship. Salutica's exact role is not stated in the documents reviewed. Chipsets came from third parties, with Realtek Semiconductor (Taiwan) both a supplier and the next-generation chip development partner.
Customer types and end-markets
| Customer type | End-market |
|---|---|
| Consumers with mild-to-moderate hearing loss | US OTC hearing aids (post-Oct 2022 FDA rule); Australian assistive listening |
| Consumers wanting situational hearing help (TV, restaurants, work) | Assistive listening devices / "hearing enhancement" consumer electronics |
| Neurodivergent users / auditory processing needs | Assistive audio (marketed on Nuheara's "Auditory Processing" page) |
| NDIS participants (Australia) | Disability-funded assistive technology |
| OEM partner (HP Inc.) | Co-branded hearing products for the US market |
| Retailers | Best Buy, Crutchfield, Amazon, Target.com (US) |
Strategy
Stated strategy (last listed period)
Nuheara's late-stage strategy had three main themes, paraphrased from FY2023–2024 releases:
-
Win the US OTC hearing-aid category. Use the first-mover FDA self-fitting clearance and the HP brand to build US retail distribution (Best Buy, Crutchfield, Amazon, Target.com). The June 2023 A$4.4m placement was earmarked to accelerate this.
-
Leapfrog on silicon. Build a next-generation medical-grade device on a single Realtek chip, aiming for smaller size and performance competitive with far costlier products from the five global hearing-aid makers (Miller, as reported by ChannelNews, Aug 2024).
-
Reach a strategic outcome. From 9 April 2024, a strategic review with Azure Capital pursued M&A while cutting investment in production and marketing to reduce external capital needs (ASX 22 May 2024).
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Date | Initiative | Owner | Outcome |
|---|---|---|---|
| Aug–Oct 2024 | Sale process via Azure Capital (15 expressions of interest) | Administrators | Only one non-binding offer, for patents only, received 16 Sep 2024; no buyer would proceed without a Realtek supply agreement |
| Nov 2024 onward | VA Loan Funding of about A$250k a month from the shareholder committee | Farjoy, Fiago and others | Kept the business trading through administration |
| 7 Feb 2025 | Shareholder-committee DOCA proposed via Orecchio SPV (initially up to 10c/$ for unsecured creditors) | Orecchio | Revised several times |
| 12–13 Mar 2025 | Revised Orecchio DOCA; total claims estimated at A$6.97m | Orecchio | Approved 17 Mar 2025 |
| Mar 2025 onward | Orecchio continues to trade the Nuheara brand (IQbuds² MAX, IQstream TV, Bluetooth Transmitter, spare parts) | Orecchio | Website updated Aug 2025 |
| By 30 Jun 2026 | Contingent "uplift" of up to 20c/$ extra to former creditors on sale of the business, or as Orecchio's performance allows after return of debt and capital | Orecchio / Trust | Outcome not publicly disclosed |
Nuheara Limited ran no strategic initiatives after 7 August 2024; control passed to the administrators. Relevant initiatives since then:
ESG commitments, transformation programmes and medium-term financial targets: none disclosed by either entity.
Products & Services
All products sat within the single hearing/hearables business. Prices are as disclosed in sources. Blank or "n/d" means not disclosed.
Commentary: Nuheara's portfolio was narrow. In practice it was one core earbud platform at a time, plus a TV accessory. The HP Hearing PRO was a re-skinned, FDA-cleared version of the Nuheara platform rather than a separate technology. Without the Realtek chip, the group had no funded next-generation product, and the administrators said this was why prospective acquirers would not bid (VA Supp. Report, s6.2).
Product Portfolio
| Product | Description / key capabilities | Target customer | Launch / latest version | Pricing | Status |
|---|---|---|---|---|---|
IQbuds (1st gen) | Wireless earbuds with hearing augmentation and noise control; flagship launch product | Early-adopter consumers with situational hearing difficulty | 2,016 | — | Discontinued |
IQbuds BOOST | Second generation; introduced Ear ID personalised hearing profile | Mild-to-moderate hearing difficulty | c.2018 (customer reviews on website reference BOOST with IQstream TV) | — | Discontinued; legacy pairing with IQstream TV |
IQbuds² MAX | Third-generation flagship: Ear ID personalisation, hybrid active noise cancellation, Speech in Noise Control, directional Focus, World Blend, high-fidelity streaming | Consumers wanting hearing help plus premium audio | 2020 (TIME Best Inventions 2020) | n/d in sources reviewed | Still listed by Orecchio on nuheara.com |
IQbuds² PRO | FDA-registered wireless hearing aid variant extending the low-cost line | US consumers with hearing loss | c.2021 | — | Legacy |
HP Hearing PRO | Self-fitting OTC hearing aid in earbud form; Ear ID self-fitting via HP Hearing app; hybrid ANC (described as the first FDA-cleared self-fitting OTC aid with hybrid ANC); Bluetooth streaming and calls; FDA 510(k) K221064 under code QUH (21 CFR 874.3325 and 800.30) | US adults with perceived mild-to-moderate hearing loss | Cleared late 2022; launched CES Jan 2023; mass production Feb 2023 | US$699 | Status under Orecchio not publicly disclosed; HP licence status unknown |
IQstream TV | Low-latency smart TV box streaming personalised stereo TV audio to IQbuds; per-user volume control via iOS/Android app; marketed as a "soundbar for your ears" | Older adults / households with TV-hearing conflict | c.2019–2020; relaunch promoted via Indiegogo bundle in 2023 | — | Listed on nuheara.com |
Bluetooth Transmitter | Connects IQbuds to non-Bluetooth sources (in-flight entertainment, stereos) | IQbuds users | — | — | Listed |
Accessories and spare parts | Charging cases, ear tips, soundport meshes | Existing users | Ongoing | — | Listed |
Ear ID (software / technology) | Self-fitting hearing-profile process; nuheara.com also hosts an NAL (National Acoustic Laboratories) hearing check | Embedded in all hearing products | Since c.2018; FDA-cleared within HP Hearing PRO | Bundled | Core IP, now owned by Orecchio |
Next-generation single-chip hearing device (Realtek) | Planned medical-grade device on a single Realtek chip, intended to match or exceed premium hearing-aid performance at lower size and cost | OTC and broader hearing-aid market | In development 2022–2024; never launched | — | Halted; the Realtek commercial/royalty agreement was never executed |
Financial Narrative
Income statement
Sources: FY2019, FY2020, FY2021 and FY2023 Appendix 4E reports (FY2022 figures from FY2023 4E comparatives); Kalkine and TipRanks aggregator data; Craft.co. FY2022 and FY2023 EPS are on a post-share-consolidation basis. The FY2023 4E restates FY2022 EPS at −15.56 cents against a pre-consolidation share count of about 1.72 billion at 30 June 2021. The consolidation ratio (implied around 1-for-20) was not directly verified.
Half-year EBITDA (the only EBITDA disclosures found, A$ millions):
Margins and growth
Gross, operating and EBITDA margins for full years are not publicly disclosed in the sources reviewed. Revenue CAGR from FY2019 to FY2023 on the 4E basis was about −19% a year (A$4.48m to A$1.93m). From the FY2021 peak to FY2023, revenue fell about 85%.
Balance sheet
Net tangible assets per share (cents, 4E): 0.74 at 30 June 2023 versus −2.66 at 30 June 2022 (FY2023 4E). Kalkine shows net cash of A$2.32m at FY2023, while Stoxray shows net debt of A$0.645m, a discrepancy that probably reflects treatment of convertible notes and lease liabilities.
Known debt at failure: Realtek A$2.5m secured convertible note (maturing 7 September 2024). Realtek's claimed secured debt was A$2,685,861.81 as at March 2025 (FCAFC 178, para 13). The administrators' liquidation statement of position recorded A$2.568m owed to the secured creditor (VA Supp. Report).
Cash flow: notes and sources
Source: TipRanks/Kalkine cash flow data (TipRanks labels columns December but the values reconcile to June fiscal year-end cash balances); FY2021 and FY2023 4E. Investing outflows mainly reflect capitalised development and intellectual property ("Payments to Acquire Intellectual Property" per the June 2023 quarterly).
Ratios
ROE, ROA, ROIC, current ratio, debt/equity, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle cannot be computed reliably from the disclosures located. They are not publicly disclosed in the reviewed sources. All return metrics would have been deeply negative given persistent losses.
Commentary on trends, inflections and drivers
FY2019–FY2020: pre-scale burn: Revenue was flat at about A$4.4–4.5m (4E basis) while net losses of A$10–12m a year were funded by equity and, from January 2020, the Lind convertible facility. Product-led revenue never reached a scale that could carry the R&D and marketing cost base.
FY2021: the false dawn: The IQbuds² MAX launch and the HP OEM programme produced a record A$12.6m. H1 FY2021 recorded positive EBITDA of A$1.48m and near-breakeven operating cash flow of −A$86k (H1 FY2021 report). This was the only period in Nuheara's listed life with positive EBITDA. It depended on a lumpy OEM order rather than recurring consumer demand.
FY2022: the cliff: With OEM revenue gone, revenue fell 69%. The net loss widened to A$14.3m, the largest in the company's history, and cash fell to A$0.44m at 30 June 2022. This made the company dependent on strategic capital. The Realtek MOU (May 2022) and Realtek's investment filled the gap but tied the company to one counterparty.
FY2023: regulatory win, commercial miss: Despite the world-first FDA self-fitting OTC clearance, FY2023 revenue halved again to A$1.93m. The company attributed part of the fall to strong prior-year second-half revenue, and also recorded inventory write-downs on Nuheara-branded stock. Cash rose to A$2.32m only because A$10.8m was raised. The June 2023 quarterly cited over A$1m in invoiced OTC hearing-aid sales to date, which was too small to change the trajectory.
FY2024: reporting failure and collapse: No accounts were lodged. Suspension (1 March 2024), a strategic review (April), a A$1.85m raise (April), cost cuts (May) and administration (August) followed. The administrators collected a FY2024 R&D tax rebate of A$840k (net of ATO offsets) during administration (VA Supp. Report).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Jurisdiction | Role | Status (Oct 2026) |
|---|---|---|---|
Nuheara Limited | Australia | Parent; ASX-listed; employing and trading entity | In liquidation (from 19 Jun 2025) |
Nuheara IP Pty Ltd (ACN 605 704 096) | Australia | Owned the group's intellectual property | Subject to DOCA; the DOCA included a clause on control of this entity. Its post-DOCA ownership was not confirmed in the documents reviewed |
Terrace Gold Pty Ltd (ACN 072 608 952) | Australia | Primarily dormant (legacy mining-era entity) | Subject to DOCA; post-DOCA status not confirmed |
Nuheara, Inc. | USA | US operations / sales | Not in administration; status not publicly disclosed |
Other subsidiaries (total of six controlled) | Reported to include UK, Canada and Netherlands entities | Regional distribution | Not in administration; status not publicly disclosed |
Orecchio Pty Ltd (ACN 684 518 723) | Australia | SPV nominated by the shareholder committee; bought the business and assets | Operating Nuheara business; has granted security to its shareholders Farjoy Pty Ltd and Fiago Pty Ltd |
Revenue by Segment
| Channel | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Total revenue from ordinary activities (AUD Mn) | 4.48 | 4.44 | 12.62 | 3.87 | 1.93 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (Half-Yearly)
| Channel | H1 FY2021 | H1 FY2022 |
|---|---|---|
OEM income (AUD Mn) | 3.77 | — |
Other / branded revenue (AUD Mn) | 3.14 | — |
Total half-year revenue (AUD Mn) | 6.91 | 2.97 |
Income Statement and Per-Share Data
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Revenue from ordinary activities per 4E (AUD Mn) | 4.48 | 4.44 | 12.62 | 3.87 | 1.93 |
Sales revenue per aggregator (AUD Mn) | 2.22 | 1.74 | 10.74 | 3.87 | 1.93 |
Cost of revenue per aggregator (AUD Mn) | 1.85 | 11.21 | 8.77 | 7.58 | 2.88 |
Gross profit per Craft.co (AUD Mn) | — | — | — | — | 0.80 |
Net loss after tax attributable to members (AUD Mn) | -10.03 | -11.69 | -7.20 | -14.34 | -11.15 |
Total comprehensive loss per aggregator (AUD Mn) | -10.03 | -11.69 | -7.89 | -14.80 | -12.62 |
Basic and diluted EPS (A$ cents) | -1.09 | -1.14 | -0.46 | -15.56 | -7.41 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Income Statement
| Metric | H1 FY2020 | H1 FY2021 | H1 FY2022 |
|---|---|---|---|
EBITDA (AUD Mn) | -3.62 | 1.48 | -3.68 |
Half-year revenue (AUD Mn) | 1.37 | 6.91 | 2.97 |
Half-year net loss (AUD Mn) | -5.73 | -0.84 | -6.01 |
Margin Analysis (%)
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Net margin on 4E revenue (%) | -224 | -263 | -57 | -371 | -578 |
Revenue growth on 4E basis (%) | -15 | -1 | 185 | -69 | -50 |
Gross margin per Craft.co (%) | — | — | — | — | 42 |
Key Financials
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Cash and equivalents (AUD Mn) | 3.22 | 4.43 | 7.28 | 0.44 | 2.32 |
Net tangible assets per aggregator (AUD Mn) | 10.11 | 5.47 | 11.79 | -2.64 | 4.43 |
Net receivables per aggregator (AUD Mn) | 0.67 | 1.57 | 1.62 | 0.55 | 3.26 |
Net debt per Kalkine (AUD Mn) | -0.68 | -1.89 | -7.28 | 0.89 | -2.32 |
Cash Flow
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | -6.50 | -5.43 | -4.07 | -9.30 | -7.48 |
Investing cash flow (AUD Mn) | -3.91 | -3.53 | -3.82 | -4.55 | -2.82 |
Financing cash flow (AUD Mn) | 5.29 | 10.18 | 10.74 | 6.98 | 12.15 |
Free cash flow (AUD Mn) | -6.61 | -8.97 | -8.03 | -13.85 | -10.36 |
Net capital raised, net of costs, per 4E (AUD Mn) | — | — | 10.95 | — | 10.83 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%) (2)
| Ratio | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Cash burn cover: year-end cash ÷ annual FCF burn (years) | 0.49 | 0.49 | 0.91 | 0.03 | 0.22 |
FCF ÷ revenue on 4E basis (%) | -148 | -202 | -64 | -358 | -536 |
Revenue by Region
| Region | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
Total revenue from ordinary activities (AUD Mn) | 12.62 | 3.87 | 1.93 |
Region Overview
| Region | Channel exposure | Direction (qualitative) | Evidence |
|---|---|---|---|
United States | HP OEM (FY2021), HP Hearing PRO OTC retail (Best Buy, Crutchfield, Amazon, Target.com), DTC | Strategic growth focus from 2022. US-based CEO John Luna appointed for the OTC launch; June 2023 placement explicitly aimed at US commercialisation | ASX releases 2022–2023 |
Australia | DTC, NDIS-funded channel | Home market; NDIS registration widened access | The Sentiment; company website NDIS page |
UK | Distributor Puretone | Minor; a UK tender/contract via Puretone referenced in FY2021 | Q2 FY2021 quarterly |
Canada, Netherlands, Hong Kong, NZ | Online / distributors | Minor | Website region selector; ROIC.ai subsidiary list |
Data Point Details
| Data point | Value | Source |
|---|---|---|
Placement price, Dec 2021 (pre-consolidation) | A$0.016 | H1 FY2022 report |
Placement price, Jun 2023 (post-consolidation) | A$0.145 | ASX placement release |
Last price before suspension | A$0.08 (27 Feb 2024) | Stoxray |
Market capitalisation around administration | About A$21m | NewsWire / Market Index, Aug 2024 |
Share price change, calendar 2023 | -41.03% | ChannelNews |
Share price change, 2024 to administration | about -30% | NewsWire / ChannelNews |
Current equity value | Nil (s104-145 declaration, 24 Jun 2025) | KPMG |
Capital Markets
| Item | Detail |
|---|---|
Analyst consensus | None identified (no sell-side coverage found) |
Dividend history / policy | No dividend ever paid |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile at failure | Single A$2.5m secured convertible note maturing 7 Sep 2024 (Realtek); VA loan funding from shareholders after appointment (repaid by DOCA: A$1,633,277 loan repayment in the deed period) |
Creditor Class Details
| Creditor class | Outcome |
|---|---|
Secured (Realtek) | A$500,000 (24 Mar 2025) against a claimed A$2.69m; security extinguished; failed appeals; adverse costs |
Priority employees | 100c/$ (A$134,419.17 paid 27 Jun 2025) or transferred to Orecchio |
Unsecured (trust beneficiaries) | Estimated initial dividend of about 47.6c/$, held back pending appeal in Sep 2025, plus a contingent uplift of up to 20c/$ by 30 Jun 2026. Trust balance A$2,703,459 at 15 Sep 2025 |
Intercompany creditors | Excluded (removing about 76% of claims by value) |
Analyst Conclusions
Guidance and consensus
No management guidance or consensus exists. Nuheara Limited is a liquidation shell and Orecchio is private. The only forward markers in the public record are (a) the contingent uplift deadline of 30 June 2026 for former creditors and (b) the liquidators' target to finalise the liquidation by 30 September 2026.
Bull case (for the Nuheara brand under Orecchio)
-
Clean slate: The DOCA removed all pre-administration claims, and secured debt was settled for A$500k. Orecchio carries the IP and FDA clearance without the listed company's burn-heavy overhead.
-
Committed owners: The shareholder committee put in about A$5.84m through the DOCA plus monthly funding, a sign of conviction and capacity to keep the business running.
-
Category tailwinds: OTC hearing aids remain a growth category, with forecasts as high as a 15% CAGR, and the company's FDA precedent and installed base could support licensing or a trade sale.
Bear case
-
Commoditised value proposition: Apple's 2024 FDA-authorised hearing-aid software in AirPods Pro, along with incumbent OTC brands, erodes the earbud-plus-hearing-aid niche.
-
No next-generation product: Without the Realtek single-chip platform, the product line rests on IQbuds² MAX technology launched in 2020.
-
Track record: Five audited years of losses (A$54m cumulative FY2019–FY2023), revenue down 85% from its peak, and buyers in 2024 unwilling to pay more than a nominal sum without a supply agreement.
Catalysts and monitorables (next 12 months)
| Monitorable | Why it matters |
|---|---|
| Distribution of the initial ~47.6c/$ dividend from the Creditors' Trust, now that High Court proceedings ended 12 Mar 2026 | Final creditor outcome |
| Whether the 20c/$ uplift was triggered by 30 Jun 2026 | Indicates Orecchio's commercial performance or a sale |
| Finalisation and deregistration of Nuheara Limited | Formal end of the listed entity |
| Any ASIC action from the liquidators' s533 reporting | Governance and legal closure |
| Orecchio product or partnership announcements (HP licence status, new chip partner) | Viability of the brand |
| Any trade sale of Orecchio / Nuheara IP | Value realisation for the shareholder syndicate |
Concluding analyst verdict
Nuheara is a cautionary case of a technically credible, under-capitalised device company whose regulatory win came too late and was spread too thin to become a durable business. In the hearing-technology segment it had real firsts. Its HP Hearing PRO became the first 510(k)-cleared self-fitting OTC hearing aid in 2022, and its products won mainstream design recognition. Commercially, though, the company never found a repeatable revenue engine. Its one profitable half-year (H1 FY2021) rested on an HP OEM order that did not recur. Revenue then fell from A$12.6m to A$1.9m in two years while annual cash burn stayed at A$8–14m.
To bridge that gap, management concentrated strategic, supply and financing risk in one counterparty. Realtek became, simultaneously, the largest shareholder, the sole secured creditor and the gatekeeper to the next-generation chip. When the commercial and royalty agreement was not signed and the A$2.5m note fell due, the company had no fallback. The administrators concluded that no buyer would pay meaningful value without that supply agreement, which makes clear that Nuheara's IP was worth little without its partner.
The restructuring was well run for creditors and employees: priority staff were paid in full, an initial unsecured dividend of about 47.6c/$ was estimated, and Realtek's challenges failed at every court level. For equity holders, however, the outcome was total loss.
The surviving business, Orecchio Pty Ltd trading as Nuheara, is a privately funded bet that a leaner owner can monetise the brand, FDA precedent and installed base. With Apple and the hearing-aid oligopoly now competing directly in OTC, and no disclosed next-generation product, its prospects are speculative. Verdict: listed equity is extinguished and uninvestable. The successor business is a high-risk niche asset whose most plausible value-realisation path is a licensing deal or trade sale rather than independent scale.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / notes | Source |
|---|---|---|---|
Justin Paul Miller | Co-founder, Managing Director and CEO | Co-founded Nuheara 2015; Executive Chair until Feb 2020, then MD/CEO; took a 60% salary cut from 16 Apr 2024 during the strategic review | VA Supp. Report; ASX release 22 May 2024 |
Cheryl Lynn Edwardes | Non-Executive Chair | — | H1 FY2020 release; VA Supp. Report |
David Buckingham | Non-Executive Director | — | VA Supp. Report; Craft.co |
Kathryn Sue Giudes | Non-Executive Director | — | VA Supp. Report |
Yean-Shao Liu | Non-Executive Director | Appointed during the Realtek relationship. Affiliation with Realtek is likely given timing but was not confirmed in the documents reviewed | VA Supp. Report |
Executive Leadership Team
| Name | Role | Period | Source |
|---|---|---|---|
David Cannington | Co-founder | — | NewsWire Aug 2024 |
John Luna | US-based CEO (Nuheara US / OTC business) | c.2022–2023 | HearingTracker 2022; ASX release Feb 2023 |
Catherine Morgan | Senior executive appointed in the Q4 FY2023 restructure (title not stated in the extract reviewed) | From mid-2023 | June 2023 quarterly |
Alan Davis | Chief Product Officer | — | Craft.co |
Jean-Marie Rudd | Chief Financial Officer | — | Craft.co |
Gillian Jowett-Blinman; Ivan Kelly | Named as contacts for the purchaser after completion | Mar 2025 | KPMG circular 21 Mar 2025 |
Governance Overview
| Attribute | Assessment |
|---|---|
Board size at failure | 5 |
Independence | 3 of 5 likely independent (Edwardes, Buckingham, Giudes). Miller was executive; Liu was probably investor-associated |
Chair/CEO separation | Yes, separated since Feb 2020 |
Gender diversity | 2 of 5 directors female (Edwardes, Giudes) |
Major Shareholders
| Holder | Description | Stake |
|---|---|---|
Realtek Semiconductor Corporation | Largest shareholder, largest creditor and only secured creditor | % not publicly disclosed in sources reviewed |
Farjoy Pty Ltd | Among the three largest holders (Jun 2023); funded administration; Orecchio shareholder / secured lender | % not disclosed |
Salter Brothers | Among the three largest holders (Jun 2023) | % not disclosed |
Fiago Construction Pty Ltd / Fiago Pty Ltd | Named "Major Shareholder"; Orecchio shareholder / secured lender | % not disclosed |
Mr Xuan Khoa Pham | Named "Major Shareholder" by administrators | % not disclosed |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Relative positioning vs Nuheara |
|---|---|---|
Sonova (Phonak; Sennheiser All-Day Clear OTC, launched US June 2023) | Prescription and OTC hearing aids | Global leader; one market study puts its audiology-devices share at over 25% (2024) |
Demant (Oticon, Philips Hearing licence) | Prescription hearing aids | Big Five incumbent; estimates underlying market growth at 4–6% a year |
WS Audiology (Signia, Widex; Sony OTC partnership) | Prescription and OTC | Big Five; partnered with Sony for consumer OTC |
GN Store Nord (ReSound, Jabra Enhance) | Prescription and OTC / DTC | Big Five; GN Hearing revenue reported as DKK 7,214m in 2025 (Ken Research) |
Starkey | Prescription, some OTC | Private US Big Five member; about 4% global share (Ivey Business Review) |
Apple (AirPods Pro hearing-aid feature) | OTC hearing-aid software in mass-market earbuds | FDA authorised as the first OTC hearing-aid software device in 2024. Arguably the most damaging threat to Nuheara's earbud-plus-hearing-aid proposition |
Sony (CRE-series OTC aids) | OTC | Consumer-electronics brand with WS Audiology technology; US$999 class pricing at Nuheara's launch |
Lexie / hearX (Bose-powered OTC) | OTC self-fitting | Direct OTC rival; around US$999 at Nuheara's launch |
Eargo | DTC / OTC invisible hearing aids | DTC rival |
MDHearing, Lucid Hearing, SoundWave Hearing | Low-cost OTC / PSAP | Price competition below US$699 |
Jabra, Samsung, Bose (consumer hearables) | Earbuds with hearing-enhancement features | Large-scale consumer competition |
Peer Comparison FY2023
| Metric | Nuheara FY2023 | GN Hearing 2025 |
|---|---|---|
Revenue (local currency M) | 1.93 | 7,214 |
Currency | AUD | DKK |
Revenue growth (%) | -50 | — |
Net margin (%) | -578 | — |
R&D intensity proxy (%) | 146 | — |
Recent Developments
The register is therefore extended back to February 2025 to capture the restructuring that defines the current entity.



